| 注册
首页|期刊导航|中国当代儿科杂志|重组人生长激素临床应用的安全性思考

重组人生长激素临床应用的安全性思考

潘慧 杜红伟

中国当代儿科杂志2024,Vol.26Issue(5):444-449,6.
中国当代儿科杂志2024,Vol.26Issue(5):444-449,6.DOI:10.7499/j.issn.1008-8830.2310001

重组人生长激素临床应用的安全性思考

Safety considerations for the clinical application of recombinant human growth hormone

潘慧 1杜红伟2

作者信息

  • 1. 北京协和医院内分泌科,北京 100032
  • 2. 吉林大学白求恩第一医院儿科,吉林长春 130021
  • 折叠

摘要

Abstract

Recombinant human growth hormone(rhGH)is an effective therapeutic drug for improving short stature.Currently,rhGH can be used for various causes of short stature,including growth hormone deficiency,and the expansion of its clinical application has raised concerns about its safety.Based on existing evidence,when rhGH is used in a standardized manner for physiological replacement therapy,its safety profile is favorable.In clinical practice,attention should be focused on short-term safety during rhGH treatment,with the combination of literature evidence and clinical experience.There is still no definitive conclusion on the long-term safety due to insufficient duration of rhGH treatment.This paper reviews the possible adverse events that may occur during rhGH treatment and their risk control measures,aiming to help clinical physicians understand the overall safety of rhGH treatment and improve its clinical standardization.

关键词

重组人生长激素/临床安全性/不良事件/风险控制

Key words

Recombinant human growth hormone/Clinical safety/Adverse event/Risk control

引用本文复制引用

潘慧,杜红伟..重组人生长激素临床应用的安全性思考[J].中国当代儿科杂志,2024,26(5):444-449,6.

中国当代儿科杂志

OA北大核心CSTPCDMEDLINE

1008-8830

访问量0
|
下载量0
段落导航相关论文